Nascent Biotech, Inc. Stock Other OTC
Equities
NBIO
US63108Q1013
Biotechnology & Medical Research
Financials (USD)
Sales 2023 | - | Sales 2024 | - | Capitalization | 31.41M |
---|---|---|---|---|---|
Net income 2023 | -2M | Net income 2024 | -2M | EV / Sales 2023 | - |
Net Debt 2023 | 217K | Net cash position 2024 | 250K | EV / Sales 2024 | - |
P/E ratio 2023 |
-2.38
x | P/E ratio 2024 |
-13.8
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 |
-
| Free-Float | 50.78% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Carrick
CEO | Chief Executive Officer | 56 | 14-07-14 |
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 16-04-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14-07-14 |
Sean Carrick
CEO | Chief Executive Officer | 56 | 14-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 16-04-03 |
1st Jan change | Capi. | |
---|---|---|
+20.53% | 127B | |
+25.36% | 117B | |
+25.56% | 27.77B | |
-19.79% | 20.44B | |
-14.36% | 16.62B | |
-14.39% | 15.92B | |
-46.67% | 14.94B | |
+12.16% | 14.74B | |
+56.54% | 14.38B |